

Skin and aesthetics · File 21
Glow 70 mg
Certificate of analysis available✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)
Blend of three peptides: BPC‑157, TB‑500 and GHK‑Cu.
Description
Vial combining three peptides: BPC‑157, a synthetic pentadecapeptide derived from a gastric-juice protein; TB‑500, a synthetic fragment of thymosin beta‑4; and GHK‑Cu, a tripeptide‑copper complex naturally present in human plasma. Total content: 70 mg, to be reconstituted with 3 mL of sterile water.
🔬 What the research says
- No published study has evaluated this three-peptide blend, in animals or in humans.
- BPC‑157: many animal studies on tendons, ligaments and the digestive tract; according to the FDA, there is virtually no published clinical data in humans.
- TB‑500: thymosin beta‑4 has been studied in animals and in a few human trials in topical or ocular form; the injectable fragment has no published clinical trials in humans.
- GHK‑Cu: human studies mainly cover topical use in skin care; injection has not been studied in humans.
Composition
| Peptide | Studied role | Labelled amount | Page |
|---|---|---|---|
| BPC‑157 | Tissue repair | 10 mg | View page |
| TB‑500 | Tissue repair | 10 mg | View page |
| GHK‑Cu | Skin and aesthetics | 50 mg | View page |
| Total | 70 mg |
The amounts measured by the laboratory for this lot are shown in the results below.
⚠️ Warnings and reported side effects
- Safety profile unknown in humans, both for each peptide and for their combination.
- Concerns raised by the FDA for BPC‑157: immune reactions, impurities, theoretical effect on blood-vessel formation (angiogenesis). TB‑500 raises the same theoretical concern.
- Possible injection-site reactions.
Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.
Certificate details
- Laboratory
- BTLabs (West Palm Beach, FL, United States)
- Report number
- IF-824-QSA-TR006-BTL26632-08
- Substance analyzed
- BPC-157, GHK-Cu, TB-500 (Glow)
- Lot
- GN2605
- Analysis date
- June 1, 2026
- Report date
- June 5, 2026
- Labelled sample content
- 70 mg
- Sample ID
- 005000040271696
Results
| Test | Method | Specification | Result |
|---|---|---|---|
| Appearance | USP <630> | Mauve powder | Mauve powderPass |
| Identity and composition (FTIR) | USP <197A> | Confirms the presence of the peptides | Confirmed, with excipient(s)Pass |
| Purity (HPLC) | USP <621> | ≥ 98 % | 99.7 %Pass |
| Measured content (HPLC) | USP <621> | 90 – 110 % de 70 mg | 75.9 mg total (108.4%)Pass GHK‑Cu 54.1 mg · BPC‑157 10.2 mg · TB‑500 11.6 mg |
| Peptide : excipient ratio | USP <1151> | Recommended 1:2 to 1:10 | 75.9 : 71.1 mg (1:0.9) |
| Total mass | USP <41> | As measured | 147.1 mg |
According to the laboratory, this analysis covers identity, purity, content and composition. It does not cover particulates, microbial contamination or endotoxins. Sterility and endotoxins are tested separately by Nelson Labs (Salt Lake City, Utah).
Original certificate

Download the certificate (PDF)
Sources
For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.
← Back to products
OH